Sivec Biotechnologies has a total of 28 patents globally, out of which 1 has been granted. Of these 28 patents, more than 82% patents are active. United States of America is where Sivec Biotechnologies has filed the maximum number of patents, followed by Canada and Japan. Parallelly, United States of America seems to be the main focused R&D centre and also is the origin country of Sivec Biotechnologies.
Sivec Biotechnologies was founded in the year 2016. The Company delivery platform uses non-pathogenic bacteria for targeted intracellular delivery of nucleic acid drugs and vaccines to mucosal epithelial cells.
Do read about some of the most popular patents of Sivec Biotechnologies which have been covered by us in this article and also you can find Sivec Biotechnologies patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over Sivec Biotechnologies patent portfolio.
How many patents does Sivec Biotechnologies have?
Sivec Biotechnologies has a total of 28 patents globally. These patents belong to 6 unique patent families. Out of 28 patents, 23 patents are active.
How Many Patents did Sivec Biotechnologies File Every Year?
Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.
| Year of Patents Filing or Grant | Sivec Biotechnologies Applications Filed | Sivec Biotechnologies Patents Granted |
| 2023 | 1 | – |
| 2022 | 3 | 1 |
| 2021 | 8 | – |
| 2020 | 8 | – |
| 2019 | 2 | – |
| 2018 | 6 | – |
How many Sivec Biotechnologies patents are Alive/Dead?
How Many Patents did Sivec Biotechnologies File in Different Countries?
Countries in which Sivec Biotechnologies Filed Patents
| Country | Patents |
| United States Of America | 5 |
| Canada | 4 |
| Japan | 3 |
| Australia | 3 |
| China | 3 |
| Europe | 3 |
| Korea (South) | 2 |
Where are Research Centres of Sivec Biotechnologies Patents Located?
The Research Centre for all the Sivec Biotechnologies patents is the United States of America.
Best Sivec Biotechnologies Patents
US20210222178A1 is the most popular patent in the Sivec Biotechnologies portfolio. It has received 6 citations so far from companies like Curevac Ag, Actym Therapeutics and Shenzhen Ruiji Biotechnology.
What Percentage of Sivec Biotechnologies US Patent Applications were Granted?
Sivec Biotechnologies (Excluding its subsidiaries) has filed 5 patent applications at USPTO so far (Excluding Design and PCT applications). Out of these 1 have been granted leading to a grant rate of 100.0%.
Below are the key stats of Sivec Biotechnologies patent prosecution at the USPTO.
Which Law Firms Filed Most US Patents for Sivec Biotechnologies?
| Law Firm | Total Applications | Success Rate |
| Mcgaw Law P C | 4 | 100.00% |
| Schlumberger Technology Corporation | 1 | 0% |
List of Sivec Biotechnologies Patents
| Sivec Biotechnologies Patents | Title |
| US11312954B2 | Transkingdom Platform For Therapeutic Nucleic Acid Delivery |
| US20220389462A1 | Transkingdom Platform For Therapeutic Nucleic Acid Delivery |
| US20220364122A1 | Bacterial Platform For Delivery Of Gene-Editing Systems To Eukaryotic Cells |
| US20220229403A1 | Flow Control Device Openings For Completion Design |
| US20210222178A1 | Microbial System For Production And Delivery Of Eukaryote-Translatable Mrna To Eukarya |
| EP3976073A4 | A Bacterial Platform For Delivery Of Gene-Editing Systems To Eukaryotic Cells |
| EP4087934A1 | A Microbial System For Production And Delivery Of Eukaryote-Translatable Mrna To Eukarya |
| EP3607070A4 | A Transkingdom Platform For Therapeutic Nucleic Acid Delivery |
| CN115335527A | Microbial System For Producing And Delivering Eukaryotic Translatable Mrna To Eukaryotes |
| CN114630670A | Bacterial Platform For Delivery Of Gene Editing Systems To Eukaryotic Cells |
| CN111133107A | A Transkingdom Platform For Therapeutic Nucleic Acid Delivery |
| WO2023211963A2 | Chimeric Invasin System |
| CA3220834A1 | Bacterial Delivery Of Antibodies, Antibody Derivatives, And Polypeptides To Eukaryotic Cells |
| CA3164395A1 | A Microbial System For Production And Delivery Of Eukaryote-Translatable Mrna To Eukarya |
| CA3142425A1 | A Bacterial Platform For Delivery Of Gene-Editing Systems To Eukaryotic Cells |
| CA3058474A1 | A Transkingdom Platform For Therapeutic Nucleic Acid Delivery |
| JP2022534437A5 | A Bacterial Platform For The Delivery Of Gene-Editing Systems Into Eukaryotic Cells |
| JP2023509964A | A Microbial System For The Production And Delivery Of Eukaryotic Translatable Mrnas To Eukaryotes |
| AU2021206307A1 | A Microbial System For Production And Delivery Of Eukaryote-Translatable Mrna To Eukarya |
| AU2020286493A1 | A Bacterial Platform For Delivery Of Gene-Editing Systems To Eukaryotic Cells |
| AU2018250169A1 | A Transkingdom Platform For Therapeutic Nucleic Acid Delivery |
| KR1020220150276A | Microbial Systems For Production And Delivery Of Eukaryotic-Translatable Mrna To Eukaryotes |
| KR1020220025757A | Bacterial Platform For Delivering Gene Editing Systems To Eukaryotic Cells |
| WO2022256519A1 | Bacterial Delivery Of Antibodies, Antibody Derivatives, And Polypeptides To Eukaryotic Cells |
| WO2021142458A1 | A Microbial System For Production And Delivery Of Eukaryote-Translatable Mrna To Eukarya |
| WO2020247321A1 | A Bacterial Platform For Delivery Of Gene-Editing Systems To Eukaryotic Cells |
| WO2018187381A3 | A Transkingdom Platform For Therapeutic Nucleic Acid Delivery |
| JP2020512823A5 | A Cross-Biota Platform For Therapeutic Nucleic Acid Delivery |
What are Sivec Biotechnologies key innovation segments?
What Technologies are Covered by Sivec Biotechnologies?
The chart below distributes patents filed by Sivec Biotechnologies